M&A Deal Summary

Brammer Bio Acquires Florida Biologix

On March 31, 2016, Brammer Bio acquired life science company Florida Biologix from Ampersand Capital Partners

Acquisition Highlights
  • This is Brammer Bio’s 1st transaction in the Life Science sector.
  • This is Brammer Bio’s 1st transaction in the United States.
  • This is Brammer Bio’s 1st transaction in Florida.

M&A Deal Summary

Date 2016-03-31
Target Florida Biologix
Sector Life Science
Buyer(s) Brammer Bio
Sellers(s) Ampersand Capital Partners
Deal Type Merger

Target

Florida Biologix

Alachua, Florida, United States
Florida Biologix is a provider of biopharmaceutical development, manufacturing, and testing services to the biotechnology industry and to biomedical research institutions.

Search 201,292 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

Brammer Bio

Cambridge, Massachusetts, United States

Category Company
Founded 2015
Sector Life Science
DESCRIPTION

Brammer Biopharmaceuticals LLC was founded early in 2015 to create a best-in-class cell and gene therapy contract development and manufacturing organization (CDMO) to enable large pharma and biotech clients to accelerate the delivery of novel medicines to improve patient health. With the in-depth biologics manufacturing knowledge and expertise of founders Mark Bamforth (CEO) and Steven Kasok (CFO), previously cofounders of Gallus Biopharmaceuticals, now as Brammer Bio, the company is positioned to accelerate the development of these important emerging technologies.


DEAL STATS #
Overall 1 of 1
Sector (Life Science) 1 of 1
Type (Merger) 1 of 1
State (Florida) 1 of 1
Country (United States) 1 of 1
Year (2016) 1 of 1

Seller(S) 1

SELLER

Ampersand Capital Partners

Wellesley, Massachusetts, United States

Investor Investor Investor Investor Investor


Category Growth Capital Firm
Founded 1988
PE ASSETS 3.0B USD
Size Large
Type Sector Focused
DESCRIPTION

Ampersand Capital Partners is a middle-market private equity group that concentrates on growth equity investment opportunities in the healthcare sector. The Firm looks to invest $10 to $100 million in businesses with $10 to $100 million of revenue. Specific areas of interests within healthcare include lab products, specialty diagnostic equipment, pharmaceutical outsourcing, and specialty pharma. Ampersand generally prefers to be the first and sole institutional investor. Ampersand was formed in 1988 and is based in Wellesley, Massachusetts.


DEAL STATS #
Overall 26 of 55
Sector (Life Science) 11 of 25
Type (Merger) 2 of 4
State (Florida) 1 of 1
Country (United States) 26 of 51
Year (2016) 4 of 9
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2016-03-24 Magellan Biosciences

Chelmsford, Massachusetts, United States

Magellan Biosciences, Inc. is a developer and manufacturer of FDA-cleared products for the testing of blood to diagnose lead poisoning in children and adults.

Sell -
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2016-08-09 Biomedical Structures

Warwick, Rhode Island, United States

Biomedical Structures LLC is a developer and manufacturer of biomedical textile implants, while MPC focuses on the development and manufacturing of precise polymer components.

Sell -